Nashville Business Journal -- Franklin-based BioMimetic Therapeutics Inc. faces a crucial test today in front of a Food and Drug Administration panel.
The biotechnology company is seeking approval for the company’s key product, bone-graft drug Augment.
BioMimetic’s (NASDAQ: BMTI) stock was hammered Tuesday, dropping about a third after the FDA released documents expressing some early concerns about the drug.
